RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nazarius S. Lamango to Antineoplastic Agents

This is a "connection" page, showing publications Nazarius S. Lamango has written about Antineoplastic Agents.
Connection Strength

1.247
  1. Tawfeeq N, Lazarte JMS, Jin Y, Gregory MD, Lamango NS. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines. Oncotarget. 2023 03 24; 14:243-257.
    View in: PubMed
    Score: 0.520
  2. Ntantie E, Fletcher J, Amissah F, Salako OO, Nkembo AT, Poku RA, Ikpatt FO, Lamango NS. Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget. 2017 May 09; 8(19):31726-31744.
    View in: PubMed
    Score: 0.346
  3. Aguilar BJ, Nkembo AT, Duverna R, Poku RA, Amissah F, Ablordeppey SY, Lamango NS. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer. Eur J Med Chem. 2014 Jun 23; 81:323-33.
    View in: PubMed
    Score: 0.281
  4. Asong G, Zhu XY, Bricker B, Andey T, Amissah F, Lamango N, Ablordeppey SY. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019 06 15; 27(12):2629-2636.
    View in: PubMed
    Score: 0.099
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support